Tofacitinib Impurity

Tofacitinib Impurity Struktur
2504210-41-5
CAS-Nr.
2504210-41-5
Englisch Name:
Tofacitinib Impurity
Synonyma:
Azilsartan medoxomil impurity331;1,3-Bis((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)propane-1,3-dione? (Tofacitinib Impurity)
CBNumber:
CB98377989
Summenformel:
C29H38N10O2
Molgewicht:
558.69
MOL-Datei:
2504210-41-5.mol

Tofacitinib Impurity Eigenschaften

Dichte
1.339±0.06 g/cm3(Predicted)
pka
10.59±0.60(Predicted)

Sicherheit

Tofacitinib Impurity Chemische Eigenschaften,Einsatz,Produktion Methoden

Tofacitinib Impurity Upstream-Materialien And Downstream Produkte

Upstream-Materialien

Downstream Produkte


Tofacitinib Impurity Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

Global( 22)Lieferanten
Firmenname Telefon E-Mail Land Produktkatalog Edge Rate
China National Standard Pharmaceutical Corporation Limited
+8615391658522
overseasales@yongstandards.com China 11927 58
Beijing Comparison Pharmaceutical Technology Co., Ltd 010-52878169 15701683040
sales@bjcomparison.com China 4704 58
Shanghai Kewel Chemical Co., Ltd. 021-64609169 18901607656
greensnown@163.com China 9911 50
Shijiazhuang yaoBo Pharmaceutical Co., Ltd. 15633056635
2880679888@qq.com China 2740 58
Hubei Yangxin Medical Technology Co., Ltd. 15374522761
3003392093@qq.com China 7935 55
TOSUN PHARM 020-61855200 13326451905
2881290884@qq.com China 7513 58
Jinan Baizhou Biological Technology Co., Ltd. 0531-88987162 18615427082
2823799053@qq.com China 497 58
Wuxi Helen Biotechnology Co., Ltd., 0510-85629785 18013409632
sales@reading-chemicals.com China 14092 58
SHENZHEN PHYSTANDARD BIO-TECH CO.,LTD 0755-0755-0755-83725350 13380397412
3001280422@qq.com China 9932 58
Hubei Ruinuo Pharmaceutical Technology Co., Ltd 0714-5316360 13165688766
123456789@qq.com China 5000 58

  • Azilsartan medoxomil impurity331
  • 1,3-Bis((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)propane-1,3-dione? (Tofacitinib Impurity)
  • 2504210-41-5
Copyright 2019 © ChemicalBook. All rights reserved